UNITY Biotechnology

2023 was a pivotal year for UNITY.     As we turn the page to 2024, we’re looking forward to continuing our mission to redefine the treatment paradigm for #DME. With many upcoming milestones, we’re thrilled to continue our momentum into the new year. Stay tuned for more to come!     #UBX1325 #JPM24 #ReimagineAging 

As an innovative leader in the space, UNITY is advancing the first senolytic therapeutic candidate for retinal diseases.     In a recent Genetic Engineering & Biotechnology News article, CEO Anirvan Ghosh, Ph.D. describes our mission and vision to target #senescent cells in the retina, regulating cellular senescence to reverse vision loss in #DME.     Read more from Kathy Liszewski in GEN: https://bit.ly/4dVBo4n   #ophthalmology #retina  

UBX1325 is designed to address the fundamental biology that drives DME disease progression – a truly differentiated approach from current #DME treatments.    At our Ophthalmology Day, CEO Anirvan Ghosh, Ph.D. explains how our #senolytic candidate aims to modify the trajectory of disease and potentially reverse retina damage, improving vision in patients.   Stay tuned as we continue advancing #UBX1325 through a Phase 2b clinical study with data expected in Q1 2025.    Access a replay of Ophthalmology Day here: https://bit.ly/3XpnuCP #AAO24 #ReimagineAging #Ophthalmology

Final call to register for our Ophthalmology Day event. TOMORROW – Don’t miss renowned #ophthalmology leaders’ presentations on our DME clinical program evaluating senolytic candidate #UBX1325, a live Q&A session and the opportunity to meet with the UNITY team on site in New York, NY. Can’t attend in-person? Virtual attendees can access the presentations online. Last chance to register: https://bit.ly/3XpnuCP

Today we recognize World Sight Day 2024 🌎👁️   At UNITY, we’re committed to advancing our senolytic candidate for retinal diseases. This #WorldSightDay, the theme “Love Your Eyes” reminds us how precious our sight is, emphasizing the importance of accessible treatments for those facing vision loss due to diseases like #DME. Today, we eagerly join the call to raise awareness, support breakthroughs in #ophthalmology, and make a lasting impact on global vision health for all. Learn more about our senolytic candidate #UBX1325 and register for our upcoming Ophthalmology Day for Investors and Analysts on October 15: https://bit.ly/3XpnuCP #WorldSightDay2024 #LoveYourEyes

Join us on October 15 for our Ophthalmology Day event — available both virtually and in-person in New York, NY.    The event will feature key presentations from leading #ophthalmology experts and the UNITY management team, with a spotlight on the latest developments from our diabetic macular edema (DME) program. A live Q&A will follow the presentations, offering the opportunity to engage directly with our team.   We look forward to seeing you there!    Register here: https://bit.ly/3XpnuCP

Join UNITY Biotechnology (#UBX) on Tues, Oct. 15 at 8am ET in New York or virtually for its Ophthalmology Day for investors and analysts, featuring Robert Bhisitkul, MD, PhD (UCSF School of Medicine), Arshad Khanani, MD, MA, FASRS (Sierra Eye Associates, University of Nevada Reno School of Medicine), and Dante Pieramici, MD (California Retina Consultants). Register here: https://bit.ly/4gBf6rd

Save the date! Join us at our Ophthalmology Day for Investors and Analysts on October 15, 2024 in New York, NY.     Our in-person and virtual event will feature presentations from prominent retina experts and members of the UNITY management team. We will focus on the latest data from our diabetic macular edema program and the ongoing Phase 2b ASPIRE study evaluating #UBX1325 head-to-head against aflibercept in DME. Additionally, a Q&A session will follow the formal presentations.     See you there!     Learn more details and register here: https://bit.ly/3ZEz66f

High blood sugar comes with a wide array of negative side effects. In diabetic patients, cellular senescence caused by sustained hyperglycemia damages the blood vessels in the retina – a key feature of #DME – and leads to vision loss. Our senolytic candidate #UBX1325 targets senescent cells in the retina, potentially reducing local inflammation and restoring vision in diabetic patients. Learn more: https://bit.ly/478Viac  

This Monday, our CEO Anirvan Ghosh, Ph.D. will provide a corporate update and company presentation at the H.C. Wainwright & Co., LLC 26th Annual Global Investment Conference. Learn more and register for the live webcast: https://bit.ly/4e0zGPz